COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide OR Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with MM Using MRD To Direct Therapy Duration (DRAMMATIC STUDY)

Protocol No
SWOG-S1803-CTN-1706-DRAMMATIC
Principal Investigator
Saurabh Chhabra
Phase
III
Summary
We are doing this study because we want to find out if this approach is better or worse than the usual approach for multiple myeloma. The usual approach is defined as care most people get for multiple myeloma.
Description
S1803, Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Participating Institutions
Moorland Reserve Health Center
Froedtert Hospital
Status
OPEN TO ACCRUAL